Viyash Scientific Q3 FY26 results, ESOP 2026 approved, SMP changes

Emphasis Of MatterResults RestatedExceptional ItemPat Growth 25pctResults View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹209.00

prior close

₹207.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%-2.2% vs market

Pharmaceuticals peers, median of 159sector-0.6%-2.4% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-2.6

15m

-2.4

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0-0.8-2.2-0.6-2.4

Next day

-0.5+1.8-2.3+1.2-1.7

-1.9+2.8-4.7+1.8-3.6

+3.4+2.3+1.1+1.3+2.1

+6.9+1.8+5.1+0.5+6.4

+3.3+0.3+3.1+0.0+3.3

+5.3+0.5+4.7-0.2+5.4

15d

+2.4-2.5+5.0-2.7+5.2

-2.8-6.3+3.6-4.6+1.8

-6.7-8.0+1.2-7.4+0.6

+5.5+8.3-2.8+2.6+2.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 cons revenue up 10.9% at Rs 8,584 million (restated); PAT Rs 485 million. 9M cons revenue up 11.9% to Rs 25,004 million, PAT up 36.9% at Rs 1,583 million. Standalone Q3 PAT near zero vs Rs 511 million prior year. Merger effective Dec 16, 2025; prior periods restated. New ESOP 2026 approved for 1.34 crore options (2.8% of capital). Exceptional items of Rs 412.60 million in Q3 for merger costs. SMP reshuffled. Auditor gave unmodified opinion with emphasis of matter on merger.

Likely market impact

Consolidated growth aided by merger consolidation; standalone Q3 weak. Amalgamation effective, prior periods restated. ESOP 2026 and SMP changes may affect future EPS and governance.